TrialAnnals of oncology : official journal of the European Society for Medical Oncology2023

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.

A J Rosenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.